How Does Oral Wegovy Outperform Foundayo in Weight Loss?

Novo Nordisk reported new indirect comparative data on April 2, 2026 that suggest its oral semaglutide (brand name Wegovy) tablet may offer differentiated efficacy and tolerability versus orforglipron (brand name Foundayo)¹, for which Eli Lilly and Company received FDA approval at the start of April.² The new data from Novo Nordisk is expected to intensify competition in the rapidly evolving oral obesity therapeutics market.

Results from the study (ORION), which was a population-adjusted indirect treatment comparison study, showed that oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg, based on data from phase 3 trials (OASIS 4 and ATTAIN-1).¹ The findings highlight growing efforts by drug developers to differentiate next-generation glucagon-like peptide-1 (GLP-1)–based therapies beyond injectable formulations.³

How does oral semaglutide compare to orforglipron in weight loss efficacy?

Across the population-adjusted study, oral semaglutide 25 mg achieved a mean weight loss advantage approximately -3 percentage points versus orforglipron 36 mg. Specifically, the estimated treatment difference reached -3.2 percentage points when accounting for real-world treatment conditions and -3.0 percentage points under an efficacy-focused scenario assuming full treatment adherence.¹

These results build on Novo Nordisk’s broader strategy to extend the clinical profile of semaglutide into oral formulations, positioning the therapy as a potentially competitive alternative to both injectable GLP-1s and emerging oral candidates.³

What do tolerability differences mean for treatment adherence?

Beyond efficacy, tolerability remains a key differentiator in the obesity drug market. In the ORION analysis, orforglipron was associated with approximately four times higher odds of discontinuation due to adverse events and nearly 14 times higher odds of discontinuation due to gastrointestinal-related events compared with oral semaglutide, according to the company. These findings point to the importance of balancing efficacy with patient adherence in chronic weight management.

“People often ask how one medication compares to another when making obesity treatment management decisions,” said Robert F. Kushner, MD, Northwestern Feinberg School of Medicine, in a company press release.¹ “Since there are no head-to-head trials comparing oral semaglutide for obesity to orforglipron, this indirect treatment comparison from the ORION study provides important information that can be used during the shared decision-making process.”

How are patient preferences shaping the oral obesity market?

Complementing the clinical analysis, a patient preference study (OPTIC) conducted from October to November 2025 found that 84% of surveyed adults favored a treatment profile similar to oral semaglutide over one resembling orforglipron. Additionally, 65% of respondents indicated that dosing requirements associated with semaglutide, such as taking the medication on an empty stomach, would not significantly disrupt daily routines.⁴

These findings suggest that patient-centric factors, including convenience and perceived tolerability, may play an increasingly influential role in treatment selection as more oral options enter the market.

Novo Nordisk’s data arrive amid growing competition in the GLP-1 and incretin-based therapeutic space, where multiple companies are advancing oral formulations to capture a broader patient population and improve accessibility. The emergence of oral alternatives to injectable therapies is widely viewed as a key next phase in market expansion, particularly as demand for obesity treatments continues to accelerate globally.⁵

The ORION study’s indirect design introduces limitations, including potential residual differences between trial populations and protocol variations. As a result, direct head-to-head studies will likely be required to confirm the comparative advantages observed.⁶ But these data reinforce a broader industry trend in which differentiation in obesity therapeutics is shifting beyond weight loss alone toward a more nuanced combination of efficacy, tolerability, and patient experience. These factors are expected to ultimately shape long-term adoption and market leadership in the obesity treatment space.

References

1. Novo Nordisk. Wegovy pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026. Published April 2, 2026. Accessed April 2, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916526
2. Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Published April 1, 2026. Accessed April 2, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
3. Pechenov S, Revell J, Will S, et al. Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Sci Rep. 2021;11(1):22521. doi: 10.1038/s41598-021-01750-0
4. Tadesse Bell S, Traina A, Bhavsar J, et al. Preferences for obesity medications among people with overweight or obesity. Poster presentation at Obesity Medicine 2026, San Diego, Calif., April 10-12, 2026.
5. Fick M, Roy M, Valle S. Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030. Jan. 12, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-sees-oral-pills-capturing-over-third-glp-1-market-by-2030-2026-01-12/
6. Michalak W, Laugesen C, Rathor N, et al. Oral semaglutide vs orforglipron in obesity – an indirect comparison. Poster presentation at Obesity Medicine 2026, San Diego, Calif., April 10-12, 2026.